Related Experiment Video
Updated: May 7, 2026
Measurement of Differentially Methylated INS DNA Species in Human Serum Samples as a Biomarker of Islet β Cell Death
Published on: December 21, 2016
Circulating non-coding RNAs as biomarkers of beta cell death in diabetes
Ryan J Farr1, Mugdha V Joglekar, Caroline J Taylor
1Diabetes and Islet biology Group, NHMRC Clinical Trials Centre, Faculty of Medicine, The University of Sydney, Level 6, Medical Foundation Building, 92-94 Parramatta Road, Camperdown, NSW 2050, Australia.
Abstract:
Death of pancreatic islet beta cells is a common feature of type 1 and 2 diabetes and often follows islet cell transplantation. Measurement of blood glucose is currently the only blunt instrument available to diagnose diabetes mellitus, and we lack tools to quantify islet cell loss or protection thereof. A class of RNA molecules (called microRNAs/miRNAs/miRs) that regulate endogenous gene expression via mRNA cleavage or translational arrest have been identified to be critical for birth, maintenance and regeneration of pancreatic beta cells. Recent demonstration that microRNAs can potentially be utilised as biomarkers due to their serum stability, has triggered increasing interest in understanding their role as regulators or biomarkers of disease. This review aims to delve into the potential of miRNA biomarkers, and whether miRNA profiles are indicators or effector of disease pathology. Furthermore, an outline for identifying and confirming islet-specific miRNA biomarkers is discussed.
Insights
MicroRNAs (miRNAs) are crucial for pancreatic beta cell health and survival in diabetes. This review explores their potential as stable biomarkers for quantifying islet cell loss and guiding diabetes treatment.
Area of Science:
- Endocrinology
- Molecular Biology
- Biomarker Discovery
Background:
- Pancreatic beta cell death is central to type 1 and type 2 diabetes and islet transplantation failure.
- Current diabetes diagnosis relies solely on blood glucose measurements, lacking methods to quantify beta cell loss.
- MicroRNAs (miRNAs) are key regulators of pancreatic beta cell development, maintenance, and regeneration.
Purpose of the Study:
- To review the potential of miRNAs as biomarkers for diabetes.
- To investigate whether miRNA profiles indicate disease pathology or are effectors of it.
- To outline methods for identifying and confirming islet-specific miRNA biomarkers.
Main Methods:
- Literature review of studies on miRNA function in pancreatic beta cells.
- Analysis of research on miRNA stability and utility as serum biomarkers.
- Discussion of strategies for identifying and validating islet-specific miRNA biomarkers.
Main Results:
- MicroRNAs play critical roles in pancreatic beta cell biology.
- Serum-stable miRNAs show promise as potential biomarkers for diabetes.
- Further research is needed to confirm miRNA profiles as indicators or effectors of disease.
Conclusions:
- MicroRNAs represent a promising avenue for developing novel biomarkers in diabetes.
- Identifying islet-specific miRNA biomarkers could enable better quantification of beta cell loss.
- This could lead to improved diagnostics and therapeutic strategies for diabetes mellitus.
